<DOC>
	<DOCNO>NCT01571635</DOCNO>
	<brief_summary>Dose find study determine safety tolerability Sotatercept ( ACE-011 ) adult Beta ( β ) -Thalassemia</brief_summary>
	<brief_title>Study Determine Safety Tolerability Sotatercept ( ACE-011 ) Adults With Beta ( β ) - Thalassemia .</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age time sign informed consent document diagnosis βthalassemia major ( include subtypes ) βthalassemia intermedia . 2 . For transfusion dependent subject : permanent transfusion dependency define require pack red blood cell ( pRBCs ) iron chelation therapy : Average transfusion requirement least 2 unit per 30 day pRBCs ( Gale , 2011 ) confirm minimum 168 day ( six month ) immediately precede enrollment ( study Day 1 ) ; No transfusionfree period 45 consecutive day 168 day immediately precede enrollment ; Mean prior transfusion Hgb level ≤ 10.5 g/dL 168 day immediately precede enrollment ( study Day 1 ) last pretransfusion Hgb immediately precede enrollment ( study Day 1 ) ≤ 10.5 g/dL . 3 . For nontransfusion dependent subject : nontransfusion dependency define transfusion free , exception ≤ one episode transfusion period minimum 168 day immediately precede enrollment ( One episode transfusion define ≤ 4 transfusion unit administer , occur within 168 day immediately precede enrollment due concurrent illness [ e.g . infection ] , [ Guidelines Clin Management Thalassaemia , 2008 ] ) . 4 . Performance status : Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . 5 . No concurrent severe hepatic disease : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 3 x upper limit normal ( ULN ) ; Albumin ≥ 3 g/dL . 6 . Serum creatinine ≤ 1.5 x ULN creatinine clearance &gt; 60 mL/min . 7 . Females childbearing potential ( FCBP ) participate study use highly effective method birth control study participation 112 day ( approximately five time mean terminal halflife sotatercept [ 23 day ] base multipledose PK data ) follow last dose sotatercept . FCBP must negative serum betahuman chorionic gonadotropin ( βHCG ) pregnancy test within 3 day sotatercept dose ( study Day 1 ) . Subjects must counsel concern measure use prevent pregnancy potential toxicity prior first dose sotatercept . A FCBP childbearing potential sexually mature woman undergone hysterectomy bilateral oophorectomy postmenopausal least 24 consecutive month ( ie , menses time precede 24 month ) . 8 . Males must agree use latex condom sexual contact FCBPs participate study 112 day follow last dose sotatercept , even undergone successful vasectomy . Subjects must counsel concern measure use prevent pregnancy potential toxicity prior first dose sotatercept . 9 . Agreement adhere study visit schedule , understand comply protocol requirement . 10 . Understand provide write informed consent . The presence follow exclude subject enrollment : 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Evidence active hepatitis C ( HCV ) infection , active infectious hepatitis B , know positive human immunodeficiency virus ( HIV ) . 3 . Known history thromboembolic event ≥ Grade 3 accord NCI CTCAE version 4.0 ( current active minor version ) . 4 . Subjects insulin dependent diabetes . 5 . Subjects major cardiac problem : Major risk heart failure Cardiac arrhythmia require treatment ( i.e atrial fibrillation ) . 6 . Treatment another investigational drug device &lt; 28 day prior study entry well prior exposure sotatercept . 7 . Use erythropoiesis stimulate agent ( ESA ) within 28 day prior enrollment ( study Day 1 ) . 8 . Subjects hydroxyurea treatment dose change last one year prior subject enrollment . 9 . Subjects longterm anticoagulant therapy , heparin warfarin . 10 . Subjects start bisphosphonates within last three month prior subject enrollment . 11 . Pregnant lactating female . 12 . Uncontrolled hypertension . Controlled hypertension protocol consider ≤ Grade 1 accord NCI CTCAE version 4.0 ( current active minor version ) 13 . A history major organ damage include : Liver disease ALT &gt; 3 x ULN histopathological evidence liver cirrhosis liver biopsy ; Heart disease ejection fraction ≥ Grade 2 accord NCI CTCAE version 4.0 ( current active minor version ) ; Kidney disease calculate creatinine clearance &lt; 40 mL/min ( CockcroftGault formula ) ; Pulmonary fibrosis pulmonary hypertension confirm specialist . 14 . Adrenal insufficiency . 15 . Heart failure classify New York Heart Association ( NYHA ) classification 3 high ( Appendix C ) . 16 . Major surgery within 30 day prior study Day 1 ( subject must completely recover previous surgery prior study Day 1 ) . 17 . History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational product ( see Investigator Brochure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Beta-Thalassaemia</keyword>
</DOC>